Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Organizational Reforms and Personnel Changes
Appointing Candidates for Director and Alternate Audit & Supervisory Board Member
Reduction of Capital Stock (Capital Reduction)
Veritas In Silico, Returning to Profitability This Year
Company Presentation
Financial Results - Fiscal Year Ended December 31, 2024
Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Under Japanese GAAP]
Patent owned by Veritas In Silico to Become Effective in Europe
Liverpool ChiroChem and VIS to Enter into a Collaboration Development & Commercialization Agreement for mRNA-targeted Small Molecule Drugs
Company Presentation
Revised Financial Forecast for FY2024
Veritas In Silico, The Current Fiscal Year Ordinary Profit Revised Downward to a Loss
Veritas In Silico Inc., January-September (Third Quarter Cumulative) Ordinary Profit Turns to Loss, July-September Ordinary Profit Loss Widens
Organizational Reforms and Personnel Changes of General Managers
Fiscal Year Ending December 2024, 3rd Quarter, Financial Results
Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Under Japanese GAAP]
Mitsubishi Gas Chemical and Veritas In Silico, Sign MOU on Joint Business of Research and Development of RNA-Targeted Drugs
Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development
Notification regarding Achievement of Milestone in Joint Drug Discovery Research with Shionogi & Co., Ltd.
[Delayed] Interim Financial Results - FY2024 1H